These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16055403)

  • 1. Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART -- case report and review of the literature.
    Baeuerle M; Schmitt-Haendle M; Taubald A; Mueller S; Walter H; Pfeiffer C; Manger B; Harrer T
    Eur J Med Res; 2005 Jul; 10(7):309-16. PubMed ID: 16055403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.
    De Luca A; Giancola ML; Ammassari A; Grisetti S; Paglia MG; Gentile M; Cingolani A; Murri R; Liuzzi G; Monforte AD; Antinori A
    J Infect Dis; 2000 Oct; 182(4):1077-83. PubMed ID: 10979902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.
    Chang L; Ernst T; Witt MD; Ames N; Walot I; Jovicich J; DeSilva M; Trivedi N; Speck O; Miller EN
    Antivir Ther; 2003 Feb; 8(1):17-26. PubMed ID: 12713060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
    Cingolani A; Fratino L; Scoppettuolo G; Antinori A
    J Neurovirol; 2005; 11 Suppl 3():38-44. PubMed ID: 16540454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Wright EJ
    Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?
    Vissers M; Stelma FF; Koopmans PP
    J Clin Virol; 2010 Dec; 49(4):231-8. PubMed ID: 20833583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
    Cheung MC; Pantanowitz L; Dezube BJ
    Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of HIV infection from the neurologic viewpoint. Therapy must reach the brain].
    von Giesen HJ; Köller H; Arendt G
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():46-50. PubMed ID: 12043074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
    Tserenpuntsag B; Kołacińska A; Jabłonowska E
    Przegl Epidemiol; 2007; 61(3):529-34. PubMed ID: 18069390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?
    Clayton A; Mughal T
    Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.
    Cook JE; Dasgupta S; Middaugh LD; Terry EC; Gorry PR; Wesselingh SL; Tyor WR
    Ann Neurol; 2005 Jun; 57(6):795-803. PubMed ID: 15852478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.